Fig 1.
The PRISMA checklist for this meta-analysis.
Table 1.
Basic characteristic of the eligible studies for additional detection rate analysis.
Table 2.
Basic characteristic of the eligible studies for recurrencerate analysis.
Fig 2.
Forest plot of the pooled additional detection rate (ADR) of Narrow-band imaging (NBI) when compared to White light cystoscopy (WLC) for non-muscle invasive bladder cancer (NMIBC) detection in per-patient analysis.
Fig 3.
Forest plot of the pooled additional detection rate (ADR) of Narrow-band imaging (NBI)when compared toWhite light cystoscopy (WLC)for non-muscle invasive bladder cancer (NMIBC) detection in per-lesion analysis.
Fig 4.
Forest plot of the pooled additional detection rate (ADR) of Narrow-band imaging (NBI)when compared toWhite light cystoscopy (WLC)for carcinoma in situ (CIS) detection in per-patient (a) and per-lesion analysis (b).
Table 3.
Diagnostic accuracy of NBI and WLC in detection of NMIBC.
Fig 5.
Forest plot of the pooled relative risk (RR) for Narrow-band imaging (NBI) compared to White light cystoscopy (WLC) at month three (a) and twelve (b).